Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Provectus Biopharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Provectus Biopharma Enters into Research Agreement with POETIC 12
Licensing Agreements 13
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 13
Equity Offering 15
Provectus Biopharma Raises USD6 Million in Public Offering of Series B Preferred Stock and Warrants 15
Provectus Biopharma Raises USD13.1 Million in Public Offering of Shares and Warrants 17
Provectus Pharma Announces Private Placement Of Shares For Up To US$30 Million 19
Provectus Pharma Completes Private Placement Of Units For US$2 Million 20
Provectus Pharma Completes Private Placement Of Units For US$2.1 Million 21
Provectus Pharma And Its Subsidiaries Complete Private Placement Of Units For US$2.5 Million 22
Provectus Pharma Files Registration Statement For A Public Offering For US$50 Million 23
Provectus Pharma Completes Registered Direct Offering Of US$5.1 Million 24
Provectus Biopharmaceuticals Inc – Key Competitors 26
Provectus Biopharmaceuticals Inc – Key Employees 27
Provectus Biopharmaceuticals Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 10, 2016: Provectus Biopharmaceuticals Reports Third Quarter 2016 Financial Results 29
Aug 09, 2016: Provectus Biopharmaceuticals Reports Second Quarter 2016 Financial Results 30
May 10, 2016: Provectus Biopharmaceuticals Reports First Quarter 2016 Financial Results 31
Mar 30, 2016: Provectus Biopharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results 32
Corporate Communications 33
Apr 20, 2017: Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board 33
Feb 23, 2017: Provectus Biopharmaceuticals Appoints Bruce Horowitz And Dominic Rodrigues As Special Advisers To The Board Of Directors 34
Dec 28, 2016: Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO 35
Nov 30, 2016: Provectus Biopharmaceuticals Announces Notification of NYSE MKT Listing Deficiency 36
Feb 29, 2016: Provectus Biopharmaceuticals Announces Leadership Changes 37
Legal and Regulatory 38
Mar 16, 2016: Provectus Announces Results of Internal Investigation 38
Product News 39
08/01/2016: Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress 39
07/14/2016: Provectus Biopharmaceuticals Establishes Australian Subsidiary 40
07/12/2016: Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at European Society for Medical Oncology 2016 Congress 41
06/09/2016: Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Annual Meeting of American Society of Clinical Oncology Now Available Online 42
06/07/2016: Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology 43
05/19/2016: Provectus Biopharmaceuticals Announces Abstract Available Online of Trials in Progress; Abstract for Poster Presentation at ASCO Annual Meeting 44
05/13/2016: Provectus Biopharmaceuticals Announces Publication of Article in Oncotarget Detailing PV-10’s Immuno-Ablative Mechanism of Action 45
04/28/2016: Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery 46
04/22/2016: Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016 47
03/18/2016: Provectus Biopharmaceuticals Announces Abstract Publicly Available for Poster Presentation on PV-10 in Combination Therapy and T Cell Mediated Immunity 48
02/24/2016: Provectus Biopharmaceuticals Announces Data on PV-10 and Co-Inhibitory Blockade to Be Presented at American Association for Cancer Research Annual Meeting 2016 49
02/03/2016: Data on Immunology Effects of Provectus Biopharmaceuticals PV-10 in Colon Cancer Presented at 11th Annual ASC Meeting 50
01/22/2016: Provectus Biopharmaceuticals Announces Immunology Data on PV-10 in Colon Cancer to Be Presented at 11th Annual ASC Meeting 51
Clinical Trials 52
Jul 13, 2016: Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting 52
May 19, 2016: Provectus Biopharmaceuticals Announces Abstract Available on PV-10 Plus Radiotherapy in Melanoma 53
Mar 16, 2016: Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma 54
Feb 29, 2016: Provectus Biopharmaceuticals Initiating Phase I Study of PV-10 in Neuroendicrine Tumors Metastatic to Liver 55
Jan 12, 2016: Provectus Biopharmaceuticals Confirms First Patients Dosed in Phase 3 Trial of PV-10 for Melanoma 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Provectus Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Provectus Biopharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Provectus Biopharma Enters into Research Agreement with POETIC 12
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 13
Provectus Biopharma Raises USD6 Million in Public Offering of Series B Preferred Stock and Warrants 15
Provectus Biopharma Raises USD13.1 Million in Public Offering of Shares and Warrants 17
Provectus Pharma Announces Private Placement Of Shares For Up To US$30 Million 19
Provectus Pharma Completes Private Placement Of Units For US$2 Million 20
Provectus Pharma Completes Private Placement Of Units For US$2.1 Million 21
Provectus Pharma And Its Subsidiaries Complete Private Placement Of Units For US$2.5 Million 22
Provectus Pharma Files Registration Statement For A Public Offering For US$50 Million 23
Provectus Pharma Completes Registered Direct Offering Of US$5.1 Million 24
Provectus Biopharmaceuticals Inc, Key Competitors 26
Provectus Biopharmaceuticals Inc, Key Employees 27
Provectus Biopharmaceuticals Inc, Subsidiaries 28